Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)

Diabetes

Volumn 48, Issue 5, 1999, Pages 1026-1034

  Young, Andrew A ^a   Gedulin, Bronislava R ^a   Bhavsar, Sunil ^a   Bodkin, Noni ^b   Jodka, Carolyn ^a   Hansen, Barbara ^b   Denaro, Maurizio ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; RATS; RATS, ZUCKER; SEQUENCE HOMOLOGY; VENOMS;

EID: 0032908654     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.5.1026     Document Type: Article

References (50)

1. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405, 1992
2. 2. Eur J Pharmacol 269:183-191, 1994
3. Fehmann HC, Jiang J, Schweinfurth J, Wheeler MB, Boyd AE, Goke B: Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 15:453-456, 1994
4. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high-potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655, 1993
5. Chen YQE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin-4 in the lizard. J Biol Chem 272:4108-4115, 1997
6. Fehmann H-C, Habener JF: Insulinotropic glucagon-like peptide-1 (7-37)/(7-36) amide: a new incretin hormone. Trends Endocrinol Metab 3:158-163, 1992
7. Egan JM, De Ore K, Greig N, Holloway H, Wang Y, Perfetti R: Glucagon-like peptide-1 restores acute-phase insulin release to aged rats (Abstract). Diabetologia 40:130A, 1997
8. Creutzfeldt WOC, Orskov C, Kleine N, Holst JJ. Willms B, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
9. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
10. Dupre J, Behme MT, Hramiak IM, Mcfarlane P, Williamson MP, Zabel P, Mcdonald TJ: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630, 1995
11. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
12. Nauck MA, Holst JJ, Willms B: Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29:411-416, 1997
13. Nauck MA, Holst JJ, Willms B, Schmiegel W: Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp Clin Endocrinol Diabetes 105:187-195, 1997
14. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV-resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278, 1998
15. Chou JZ, Place GD, Waters DG, Kirkwood JA, Bowsher RR: A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. J Pharm Sci 86:768-773, 1997
16. Eng J: Prolonged effect of exendin-4 on hyperglycemia of db/db mice (Abstract). Diabetes 45:152A, 1996
17. Bhavsar S, Lachappell R, Watkins J, Young A: Comparison of glucose-lowering effects of exendin-4 and GLP-1 in diabetic db/db mice (Abstract). Diabetes 47:192A, 1998
18. Bodkin N, Hansen B, Young A: Dose response for glucose lowering by exendin-4 in diabetic rhesus monkeys (Macaca mulatta) (Abstract). Diabetes 47:93A, 1998
19. 1c in diabetic fatty Zucker rats (Abstract). Diabetes 47:280A, 1998
20. 1c and improves insulin sensitivity in diabetic fatty Zucker rats (Abstract). Diabetologia 41:197A, 1998
21. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
22. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentration. Diabetologia 42:45-50, 1999
23. Bhavsar S, Watkins J, Young A: Comparison of central and peripheral effects of exendin-4 and GLP-1 on food intake in rats (Abstract). In Program and Abstracts: 80th Annual Meeting of the Endocrine Society. Bethesda, MD, The Endocrine Society, 1998, p. 433
24. Jodka C, Gedulin B, Young A: Exendin-4 potently regulates gastric emptying in rats (Abstract). Diabetes 47:403A, 1998
25. Parkes D, Pittner R, Ackerman J, Watts L, Young A: Insulinotropic actions of exendin-4 and GLP-1 in isolated rat pancreatic islets. In Programs and Abstracts: 80th Annual Meeting of the Endocrine Society. Bethesda, MD, The Endocrine Society, 1998, p. 275
26. Groop L, Widen E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C, Eriksson J: Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:599-605, 1989
27. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR; Insulin, glibenclamide, or metformin treatment for non-insulin-dependent diabetes: heterogeneous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res Clin Pract 79:69-76, 1992
28. Jeng CY, Hollenbeck CB, Wu MS, Chen YD, Reaven GM: How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes? Diabet Med 6:303-308, 1989
29. Khoursheed M, Miles PD, Gao KM, Lee MK, Moossa AR, Olefsky JM: Metabolic effects of troglitazone on fat-induced insulin resistance in the rat Metabolism 44:1489-1494, 1995
30. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA: Metabolic effects of troglitazone in the Goto-Kakizaki rat, a nonobese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 46:192-198, 1997
31. Lee MK, Olefsky JM: Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44:1166-1169, 1995
32. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-046 in NIDDM subjects. Diabetes Care 15:193-203, 1992
33. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH: A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high-fat feeding of rats. Metabolism 38:1089-1093, 1989
34. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185, 1998
35. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM: TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46:1678-1683, 1997
36. Leblanc H, Thote A, Chatellier G, Passa P: Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics. Diabetes Metab 16:93-97, 1990
37. Matthews DR, Hosker JP, Stratton I; The physiological action of gliclazide: β-cell function and insulin resistance. Diabetes Res Clin Pract 14 (Suppl. 2):S53-S59, 1991
38. Hirshman MF, Horton ES: Glyburide increases insulin sensitivity and responsiveness in peripheral tissues of the rat as determined by the glucose clamp technique. Endocrinology 126:2407-2412, 1990
39. Vestergaard H, Weinreb JE, Rosen AS, Bjorbaek C, Hansen L, Pedersen O, Kahn BB: Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in non-insulin-dependent diabetes mellitus subjects: a longitudinal study. J Clin Endocrinol Metab 80:270-275, 1995
40. Simpson HC, Sturley R, Stirling CA, Reckless JP: Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. Diabet Med 7:143-147,1990
41. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KG, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232, 1996
42. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
43. U.K. Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
44. Mizuno A, Kuwajima M, Ishida K, Noma Y, Murakami T, Tateishi K, Sato I, Shima K: Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46:745-749, 1997
45. Lovejoy J, Newby FD, Gebhart SSP, Digirolamo M: Insulin resistance in obesity is associated with elevated basal lactate levels and diminished lactate appearance following intravenous glucose and insulin. Metabolism 41:22-27, 1992
46. Bogardus C, Lillioja S, Stone K, Mott D: Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 73:1185-1190, 1984
47. Young AA, Bogardus C, Wolfe-Lopez D, Mott DM: Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 37:303-308, 1988
48. Ortmeyer HK, Bodkin NL, Hansen BC: Insulin-mediated glycogen synthase activity in muscle of spontaneously insulin-resistant and diabetic rhesus monkeys. Am J Physiol 265:R552-R558, 1993
49. Rink TJ, Larson E, Young AA, Gedulin B: Effects of amylin on lactate metabolism in the rat studies using hyperactemic/hyperglycemic clamps (Abstract). Diabetologia 37:117A, 1994
50. Gedulin B, Larson E, Young AA, Rink TJ: Combined hyperlactemic and hyperglycemic clamps in anesthetized rats with acute pancreatectomy or somatostatin infusion: effects of amylin on endogenous lactate and glucose production. Program and Abstracts: 76th Annual Meeting of the Endocrine Society. Bethesda, MD, The Endocrine Society, 1994, p. 373